Table: Solasia Pharma -9-MTH group results (IFRS)

Solasia Pharma KK

14/11/2025 06:37

Nov 14 (Reuters)- 
              Solasia Pharma K. K. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   9 months ended      9 months ended       Year to  
                  Sep 30, 2025        Sep 30, 2024      Dec 31, 2025 
                     LATEST             YEAR-AGO          COMPANY    
                     RESULTS             RESULT           FORECAST   
  Sales              91 mln              81 mln             1.30     
                   (+12.6 pct)         (-86.5 pct)      (+310.2 pct) 
  Operating       loss 713 mln        loss 892 mln      loss 650 mln 
  Pretax          loss 725 mln        loss 892 mln      loss 650 mln 
  Net             loss 726 mln        loss 871 mln      loss 650 mln 
  EPS Basic       loss 3.16 yen       loss 4.53 yen    loss 2.50 yen 
  EPS Diluted     loss 3.16 yen       loss 4.53 yen                  
  Ann Div                                  NIL              NIL      
  -Q2 Div              NIL                 NIL                       
  -Q4 Div                                  NIL              NIL      
 
  NOTE - Solasia Pharma K. K.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4597.T